Table 1

Demographics and clinical characteristics

Nonactive disease

Active disease

Total

Patients

14

60

74

Age (years)

37.5 (26.2 to 37.5)

34.0 (28.0 to 40.0)

35.0 (27.5 to 42.0)

Female/male

11/3

52/8

63/11

Race: African American, Hispanic, White

7, 7, 0

26, 27, 7

33, 34, 7

SLEDAI

2 (0 to 5.25)

10 (4 to 17)

10 (4 to 16)

Renal SLEDAI

0

8 (4 to 8)

4 (4 to 8)

Renal pathology

World Health Organization classification

II

4

8

12

III

1

16

17

IV

3

25

28

V

6

7

13

Unknown

0

3

3

Protein:creatinine ratio

0.190 ± 0.040

1.536 ± 0.229*

1.278 ± 0.195

Serum creatinine

1.422 ± 0.403

1.738 ± 0.191

1.677 ± 0.172

Positive anti-dsDNA (total tested)

4 (11)

30 (50)

34 (61)

Hypocomplementemia (total tested)

9 (11)

35 (46)

44 (57)

Current medications

Prednisone

10

47

57

Mycophenolic acid

5

24

29

Cyclophosphamide

0

3

3

Azathioprine

2

3

5

Methotrexate

1

1

2

Cyclosporin A

0

1

1

Angiotensin blocking agents

9

32

41

Hydrochloroquine

7

26

33

Data presented as n, median (interquartile range) or mean ± standard error. Nonactive disease, renal Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) = 0; active disease, renal SLEDAI > 0. dsDNA, double-stranded DNA. *P < 0.01, active versus nonactive.

Singh et al. Arthritis Research & Therapy 2012 14:R164   doi:10.1186/ar3912